A study conducted sensitivity assays of growth inhibition and apoptosis induction for the RAF inhibitor (RAFi), vemurafenib, and the MEK inhibitor (MEKi), selumetinib, against a panel of 16 BRAF-mutant melanoma cell lines. The gene discussed is MAP2K7; the disease is melanoma.